While You Were Waiting For Praluent, FDA Approved Four Other Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA clears AbbVie’s Technivie, Novartis’ Odomzo, a new indication for Amgen’s Kyprolis and Bristol’s Daklinza July 24 before its much anticipated approval of Regeneron/Sanofi’s Praluent.
You may also be interested in...
Curis Set For Transformative Year With Erivedge Skin Cancer Approval
Approved nearly six weeks before the March 8 PDUFA date, Erivedge (vismodegib) will be available to treat advanced basal cell cancers in a week or two for about $7,500 a month wholesale, partner Genentech said.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.